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Abstract
The synthesis and characterization di-n-butyl- and dimethyltin D-(+)-camphorates, respectively
compounds 1 and 2, are reported. Compound 1 displays antitumoural activity in vitro, and is more
active than cisplatin, 5-fluorouracil and etoposide against seven tumoural cell lines of human origin,
but less active than methotrexate and doxorubucin.
Several diorganotin derivatives of dicarboxylic acids are active in vitro against human tumoural cell
lines1-6. Nevertheless, diorganotin derivatives of dicarboxylic acids with proven antitumour activity in
vitro remain rather rare. The present paper reports the synthesis and characterization of two novel
diorganotin dicarboxylates, di-n-butyl- and dimethyltin D-(+)-camphorates, in order to further
investigate the influence of the structure of such a dicarboxylate moiety on antitumour properties7.
The antitumour activity of the di-n-butyltin compound is presented, that of the dimethyltin
compound being provided for comparison.
Di-n-butyl- and dimethyltin D-(+)-camphorates, respectively compounds 1 and 2, were prepared by
condensing the appropriate diorganotin oxide with camphoric acid in refluxing toluene/ethanol 4/1
under elimination of the azeotrope water/toluene/ethanol81. They were recrystallized from
ethanol/petroleum ether, m.p. 138-140 C, yield" 90%, and methylene chloride/hexane, m.p. 258-
259 C, yield: 96%, respectively. The MSssbauer parameters of compounds 1 and 2 are
respectively I.S." 1.39, Q.S.’ 3.32, ]-’1: 1.06, 1"2:0.92 and I.S." 1.35, Q.S" 3.89, FI" 0.93, F2" 1.02






The molecular weight of 2 was determined by cryoscopy in camphor (calc. for C12H2oO4Sn 347;
found" 343 + 52 Dalton.
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t: 2.86 [9] t: 2.85 [9]
m" 2.22-2.10 m" 2.22-2.10
m" 1.90-1.77 m" 1.89-1.76
ddd: 2.53 [12, 8, 8] ddd: 2.53 [12, 8, 8]








H7a s: 1.35 s: 1.33 C7a 22.7 22.8
H7b S: 0.87 S: 0.83 C7b 21.5 21.5
H8 s: 1.23 s: 1.22 C8 22.4 21.9
H.I m: 1.66-1.51 s: 0.91 (81) Co 25.1 (5;941566) 4.4 (660/630)
CI 26.8 (35)
H, m: 1.48-1.34 C, 26.4 (97)
Hs t: 0.87 [7] Cs 13.5
Table 1" 1H and 13C NMR data of compounds 1 and 2 (CDCI3). Chemical shifts in ppm vs. TMS; nJ(1H,1H)
coupling constants (between brackets), 2j(1H,IgSn) and nj(13C,119/117Sn) coupling constants in Hz (bold in
parentheses); d’ doublet; t: triplet; s: singlet; m: complex pattern.
The 117Sn NMR chemical shifts 5(117Sn)(CDCI3) (ppm) of compounds 1 and 2 are respectively
-150.7 and -124.8 ppm. These values are in agreement with the structure proposed, the absence
of concentration effect (30 and 100 mg/0.5 ml) excluding any monomer- oligomer equilibrium.
Compounds 1 and 2 were screened in vitro against seven tumoural cell lines of human origin: MCF-
7 and EVSA-T, two mammary tumours, WiDr, a colon carcinoma, IGROV, an ovarian cancer, M19
MEL, a melanoma, A498, a renal cancer, and H226, a non-small cell lung cancer, as water/ethanol
99/1 solutions.
The results of the antitumoural tests are summarized in table 2 and compared with the inhibition
doses ID50 obtained for some clinically used reference compounds11,12, cisplatin, 5-fluorouracil,
etoposide, methotrexate and doxorubicin.
Compounds MCF-7 EVSA-T WiDr IGROV M19.MEL A498 H226
1 49 28 100 45 66 49 178
2 1342 903 3504 1006 1111 1548 764
Cisplatin 699 422 967 69 558 2253 3269
5-Fluorouracil 750 475 225 297 442 43 340
Etoposide 2594 317 150 580 505 314 3934
Methotrexate 8 5 <3 7 23 37 2287
Doxorubicin 0 8 11 60 6 90 99
Table 2. Inhibition doses ID5o of compounds 1 and 2 and of some reference compounds11 against seven
tumoural cell lines of human origin
Compound 1 is more active than cisplatin, 5-fluorouracil and etoposide against all cell lines, but less
active than methotrexate and doxorubucin. The dimethyltin compound 2 is inactive, as usually13.
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